Applied DNA Sciences, Inc. (NASDAQ:APDN) Sees Large Increase in Short Interest

Applied DNA Sciences, Inc. (NASDAQ:APDNGet Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totalling 2,140,000 shares, an increase of 23.7% from the August 15th total of 1,730,000 shares. Based on an average daily volume of 9,760,000 shares, the short-interest ratio is presently 0.2 days.

Applied DNA Sciences Trading Down 2.2 %

NASDAQ APDN traded down $0.03 during mid-day trading on Monday, hitting $1.34. The company’s stock had a trading volume of 659,777 shares, compared to its average volume of 3,755,347. The firm has a market capitalization of $13.69 million, a price-to-earnings ratio of -0.08 and a beta of 0.37. The company’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $3.40. Applied DNA Sciences has a twelve month low of $0.31 and a twelve month high of $28.20.

Applied DNA Sciences (NASDAQ:APDNGet Free Report) last issued its quarterly earnings data on Thursday, August 8th. The technology company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $1.11. Applied DNA Sciences had a negative net margin of 214.42% and a negative return on equity of 138.41%. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the company earned ($4.80) earnings per share. As a group, research analysts forecast that Applied DNA Sciences will post -1.8 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. StockNews.com assumed coverage on shares of Applied DNA Sciences in a research report on Friday, August 16th. They set a “sell” rating on the stock. HC Wainwright cut their price target on Applied DNA Sciences from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, June 10th.

Read Our Latest Stock Analysis on Applied DNA Sciences

Institutional Trading of Applied DNA Sciences

An institutional investor recently raised its position in Applied DNA Sciences stock. AMH Equity Ltd grew its position in Applied DNA Sciences, Inc. (NASDAQ:APDNFree Report) by 46.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 540,385 shares of the technology company’s stock after purchasing an additional 170,385 shares during the period. AMH Equity Ltd owned about 63.57% of Applied DNA Sciences worth $222,000 at the end of the most recent reporting period. 22.22% of the stock is owned by institutional investors and hedge funds.

About Applied DNA Sciences

(Get Free Report)

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.

See Also

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.